Skip to main content
. 2015 Dec 28;10(12):e0145218. doi: 10.1371/journal.pone.0145218

Fig 7. Reduced ICAM-1 binding in Rras −/− T cells.

Fig 7

(A) Splenic T cells were treated with CCL21 (0.5 μg/ml) for 5 min, washed and incubated with ICAM-1/Fc (10 μg/ml) for 30 min. Bound Fc was detected by a PE-conjugated goat anti-human IgG followed by flow cytometry analysis. (B) Quantification of results is shown as the percentage of ICAM-1 binding. Bars, SD. *p<0.05, two-tailed t-test. ns, not significant. (C) Quantification of T cells binding to immobilized Fc and ICAM-1/Fc in 96-well plates in the presence or absence of CCL21 (1 μg/ml). Results are presented as ICAM-1 binding relative to untreated controls. Three mice were used per group. Bars, SD. Two-tailed t-test. **p<0.005, ns, not significant. (D) The relative surface expression of CD11a and CD18 on splenic T cells were quantified by FACS. Results are from six animals per group. Bars, SD. Two-tailed t-test. *p<0.05, **p<0.005, ns, not significant. (E) Cell adhesion assays were carried out in 2H-11 endothelial cells. CFSE-labeled T cells were added in triplicates to 2H-11 pretreated without or with TNF-α. Bound cells were quantified by counting the number of green cells from three randomly selected fields. Data are from two mice per group. Bars, mean values. Two-tailed t-test. *p<0.05, **p<0.005.